Clinical Trial Update: Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating an intravenous azithromycin formulation for pelvic inflammatory disease in Japan has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pelvic Inflammatory Disease

Drugs mentioned

• Azithromycin IV formulation (azithromycin)

Snippet

Sponsor: Pfizer | Conditions: Pelvic Inflammatory Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-11-03